---
date: 2017-06-13
title: Summary of PKPD of biotech drugs chapter 12
categories: [medicine, english, pharmacology]
tags: [medicine, biothch-drug, pk, pd, new-drug-development]
banner: 'http://www.nature.com/nrd/journal/v9/n4/images/nrd3003-f1.jpg'
bibliography: 'bib/biotechch12.bib'
---

```{r include = FALSE}
library(knitcitations)
cleanbib()
cite_options(citation_format = "pandoc", style = "markdown")
```

This is a summary of the book chapter 12. `r citep(read.bibtex("bib/biotechdrugs.bib"))`
<!--more-->

## Hormones

- Homeostatic feedback systems
- example: insulin, PTH, cytokines
- insulin: stimulating glucose update into cells
    - half-life: 5-6
    - SC dosing - flip-flop kinetics: C~max~, T~max~
- PTH
    - Teriparatide (N-terminal 34-mer of full-length PTH, approved)
    - Anabolic effect - stimulation of osteoblasts
    - PTH1R

## Cytokine

- HGF - nonlinearity
- Thrombopoietin analogue (PEG-rHuMGDF) - Modeling of thrombopoietic effects

## Soluble Receptors

- Etanercept - TNF receptor binding fusion protein
    - PASI (Psoriasis Area and Severity Index)
    - Sigmoid E~max~-model - EC50 2ug/ml

## Monoclonal antibodies

- Table 12.2, Table 12.3, Table 12.3 - **Approved therapeutic monoclonal antibodies**
- Anti-TNF-$\alpha$ antibodies
    - infliximab (chimeric antibody)
    - fully humanized (adalimumab)
    - RA biomarker: ACR20 and EULAR improvement
- Therapeutic Antibodies in Oncology
    - Rituximab - anti-CD20 -> B cells (ADCC, CDC, apoptosis)
    - PK of rituximab - nonlinear in multiple dose
    - CLL dose > NHL dose: larger tumor burden and antigen sink
    - Bevacizumab: humanized IgG1 monoclonal antibody that binds and inhibits VEGF interaction with its receptor Flt-1 and KDR -> angiogenesis.
    - Trastuzumab: targeting HER2 receptor

\* The banner is inserted from the article `r citep("10.1038/nrd3003")`.

![Comparison of PK](/assets/smallvsbio.jpg)

## Reference

`r write.bibtex(file="bib/biotechch12.bib")`
